Table 2.

Summary of ongoing NCT registered clinical trials of T regulatory Cell-based therapy for COVID-19 (updated on January 28, 2024).

NCT number	Title	Study Design	Specification of the biological product	Number of patients	Phase/Status	Location
NCT04468971	REgulatory T Cell infuSion fOr Lung Injury Due to COVID-19 PnEumonia (RESOLVE)	Randomized placebo controlled	Cryopreserved, off-the-shelf, cord blood-derived T regulatory cells	45	Phase I - completed	USA
NCT04482699	Phase I/Phase II Trial of Allogeneic Hybrid TREG/Th2 Cell (RAPA-501-ALLO) Therapy for COVID-19-Related ARDS	Randomized placebo-controlled	Allogeneic off-the-shelf RAPA-501 cells	1	Terminated. Change in an eligible patient population	USA
NCT05027815	A Phase 1/2a Study of Cryopreserved Ex Vivo Expanded Polyclonal CD4+CD127lo/-CD25+ T Regulatory Cells (cePolyTregs) for the Treatment of Acute Respiratory Distress Syndrome (ARDS) Associated With SARS-CoV-2 Infection (regARDS)	Treated arm	Cryopreserved Ex Vivo Expanded Polyclonal CD4+CD127lo/−CD25+ T Regulatory Cells	7	Terminated. A decrease in COVID-19 cases made further enrollment infeasible.	USA

NCT number: National Clinical Trial Number. Data retrieved from https://clinicaltrials.gov/search?cond=tregs%20covid.